Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
MARLBOROUGH, MA - Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC) announced today that the US Food and Drug Administration (FDA) has cleared the C ...
Satisfied Users & 
Approved Press Releases
